FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089752957> ?p ?o ?g. }

• W3089752957 endingPage "1066" @default.
• W3089752957 startingPage "1049" @default.
• W3089752957 abstract "Stemming from a myriad of genetic and epigenetic alterations, triple-negative breast cancer (TNBC) is tied to poor clinical outcomes and aspires for individualized therapies. Here we investigated the therapeutic potential of co-inhibiting integrin-dependent signaling pathway and BRD4, a transcriptional and epigenetic mediator, for TNBC.Two independent patient cohorts were subjected to bioinformatic and IHC examination for clinical association of candidate cancer drivers. The efficacy and biological bases for co-targeting these drivers were interrogated using cancer cell lines, a protein kinase array, chemical inhibitors, RNAi/CRISPR/Cas9 approaches, and a 4 T1-Balb/c xenograft model.We found that amplification of the chromosome 8q24 region occurred in nearly 20% of TNBC tumors, and that it coincided with co-upregulation or amplification of c-Myc and FAK, a key effector of integrin-dependent signaling. This co-upregulation at the mRNA or protein level correlated with a poor patient survival (p < 0.0109 or p < 0.0402, respectively). Furthermore, we found that 14 TNBC cell lines exhibited high vulnerabilities to the combination of JQ1 and VS-6063, potent pharmacological antagonists of the BRD4/c-Myc and integrin/FAK-dependent pathways, respectively. We also observed a cooperative inhibitory effect of JQ1 and VS-6063 on tumor growth and infiltration of Ly6G+ myeloid-derived suppressor cells in vivo. Finally, we found that JQ1 and VS-6063 cooperatively induced apoptotic cell death by altering XIAP, Bcl2/Bcl-xl and Bim levels, impairing c-Src/p130Cas-, PI3K/Akt- and RelA-associated signaling, and were linked to EMT-inducing transcription factor Snail- and Slug-dependent regulation.Based on our results, we conclude that the BRD4/c-Myc- and integrin/FAK-dependent pathways act in concert to promote breast cancer cell survival and poor clinical outcomes. As such, they represent promising targets for a synthetic lethal-type of therapy against TNBC." @default.
• W3089752957 created "2020-10-08" @default.
• W3089752957 creator A5002727383 @default.
• W3089752957 creator A5003394756 @default.
• W3089752957 creator A5003894121 @default.
• W3089752957 creator A5005844055 @default.
• W3089752957 creator A5008517264 @default.
• W3089752957 creator A5011907117 @default.
• W3089752957 creator A5018576436 @default.
• W3089752957 creator A5020589993 @default.
• W3089752957 creator A5021562291 @default.
• W3089752957 creator A5022802322 @default.
• W3089752957 creator A5025940421 @default.
• W3089752957 creator A5027062741 @default.
• W3089752957 creator A5031153079 @default.
• W3089752957 creator A5034762378 @default.
• W3089752957 creator A5037989560 @default.
• W3089752957 creator A5038784500 @default.
• W3089752957 creator A5039960048 @default.
• W3089752957 creator A5043356539 @default.
• W3089752957 creator A5043930514 @default.
• W3089752957 creator A5048543466 @default.
• W3089752957 creator A5052044401 @default.
• W3089752957 creator A5053212235 @default.
• W3089752957 creator A5054656489 @default.
• W3089752957 creator A5071346964 @default.
• W3089752957 creator A5071813677 @default.
• W3089752957 date "2020-10-02" @default.
• W3089752957 modified "2023-10-07" @default.
• W3089752957 title "BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways" @default.
• W3089752957 cites W1602880342 @default.
• W3089752957 cites W1630547983 @default.
• W3089752957 cites W1908864745 @default.
• W3089752957 cites W1956409007 @default.
• W3089752957 cites W1969820174 @default.
• W3089752957 cites W1971875278 @default.
• W3089752957 cites W1977572305 @default.
• W3089752957 cites W1981366726 @default.
• W3089752957 cites W1981990919 @default.
• W3089752957 cites W1987276771 @default.
• W3089752957 cites W1994447945 @default.
• W3089752957 cites W1999287219 @default.
• W3089752957 cites W1999991643 @default.
• W3089752957 cites W2002654154 @default.
• W3089752957 cites W2006163902 @default.
• W3089752957 cites W2013172326 @default.
• W3089752957 cites W2015011408 @default.
• W3089752957 cites W2017175385 @default.
• W3089752957 cites W2037896546 @default.
• W3089752957 cites W2041746617 @default.
• W3089752957 cites W2043398720 @default.
• W3089752957 cites W2044423100 @default.
• W3089752957 cites W2045495339 @default.
• W3089752957 cites W2048117957 @default.
• W3089752957 cites W2055215337 @default.
• W3089752957 cites W2064335213 @default.
• W3089752957 cites W2068652698 @default.
• W3089752957 cites W2073068301 @default.
• W3089752957 cites W2085740859 @default.
• W3089752957 cites W2090200585 @default.
• W3089752957 cites W2090465837 @default.
• W3089752957 cites W2091506455 @default.
• W3089752957 cites W2096283457 @default.
• W3089752957 cites W2096497892 @default.
• W3089752957 cites W2114540112 @default.
• W3089752957 cites W2114952553 @default.
• W3089752957 cites W2120572492 @default.
• W3089752957 cites W2124393085 @default.
• W3089752957 cites W2124820482 @default.
• W3089752957 cites W2129485273 @default.
• W3089752957 cites W2134539328 @default.
• W3089752957 cites W2144436850 @default.
• W3089752957 cites W2146078095 @default.
• W3089752957 cites W2147111825 @default.
• W3089752957 cites W2150469988 @default.
• W3089752957 cites W2157903567 @default.
• W3089752957 cites W2166334861 @default.
• W3089752957 cites W2169287961 @default.
• W3089752957 cites W2172697812 @default.
• W3089752957 cites W2173602200 @default.
• W3089752957 cites W2263799391 @default.
• W3089752957 cites W2314423784 @default.
• W3089752957 cites W2318381116 @default.
• W3089752957 cites W2333877478 @default.
• W3089752957 cites W2375577403 @default.
• W3089752957 cites W2403308793 @default.
• W3089752957 cites W2469223980 @default.
• W3089752957 cites W2522947591 @default.
• W3089752957 cites W2580617915 @default.
• W3089752957 cites W2586373162 @default.
• W3089752957 cites W2779743226 @default.
• W3089752957 cites W2795441251 @default.
• W3089752957 cites W2891378535 @default.
• W3089752957 cites W2156738969 @default.
• W3089752957 doi "https://doi.org/10.1007/s13402-020-00537-1" @default.
• W3089752957 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7716866" @default.
• W3089752957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33006750" @default.
• W3089752957 hasPublicationYear "2020" @default.

• next